(19)

(11)

EP 4 469 078 A1

(12)

(43) Date of publication: 04.12.2024 Bulletin 2024/49 (21) Application number: 23702039.1 (22) Date of filing: 19.01.2023

(51) International Patent Classification (IPC):  A61K 39/12(2006.01) C07K 14/045(2006.01) C07K 14/005(2006.01) (52) Cooperative Patent Classification (CPC): A61K 39/12; C07K 14/005; C12N 2710/16122; C12N 2710/16134; A61P 31/20; C07K 2319/73; C07K 2319/70; C12Y 401/03016; C12Y 401/02014; C07K 14/035; A61K 2039/5252; A61K 2039/575; A61P 31/22; A61K 2039/51; C07K 2319/50; C07K 2319/02; C07K 2319/21 (86) International application number: PCT/IB2023/050457 (87) International publication number: WO 2023/144665 (03.08.2023 Gazette 2023/31)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA Designated Validation States: KH MA MD TN (30) Priority: 28.01.2022 US 202263304193 P 08.06.2022 US 202263350123 P (71) Applicant: GlaxoSmithKline Biologicals S.A. 1330 Rixensart (BE)	(72) Inventors: BIANCUCCI, Marco Rockville, Maryland 20850 (US) WAHOME, Newton Muchugu Rockville, Maryland 20850 (US) (74) Representative: Furstoss, Olivia Aline  GSK Legal & Compliance - Global Patents 79 New Oxford Street London WC1A 1DG London WC1A 1DG (GB)